Supplementation with B vitamins or n-3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids (SU.FOL.OM3) randomized trial

Am J Clin Nutr. 2012 Jul;96(1):208-14. doi: 10.3945/ajcn.112.035253. Epub 2012 May 30.

Abstract

Background: Dietary factors might affect depressive symptoms.

Objective: In secondary data analyses, we examined effects of supplementation with B vitamins or n-3 (omega-3) fatty acids on depressive symptoms in cardiovascular disease survivors.

Design: The SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids (SU.FOL.OM3) trial was a secondary prevention trial (2003-2009; n = 2501) in which individuals aged 45-80 y were randomly assigned, by using a 2 × 2 factorial design, to receive 0.56 mg 5-methyl-tetrahydrofolate and vitamins B-6 (3 mg) and B-12 (0.02 mg); EPA and DHA (600 mg) in a 2:1 ratio; B vitamins and n-3 fatty acids; or a placebo. Depressive symptoms were evaluated at years 3 and 5 with the 30-item Geriatric Depression Scale (GDS). Overall and sex-specific ORs and 95% CIs were estimated in 2000 participants by using factorial logistic regression.

Results: After a median of 4.7 y of supplementation, there was no association between allocation to receive B vitamins and depressive symptoms. However, the allocation to receive n-3 fatty acids was positively associated with depressive symptoms (GDS >10) in men (adjusted OR: 1.28; 95% CI: 1.03, 1.61) but not in women.

Conclusions: We showed no beneficial effects of a long-term, low-dose supplementation with B vitamins or n-3 fatty acids on depressive symptoms in cardiovascular disease survivors. The adverse effects of n-3 fatty acids in men merit confirmation.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / therapeutic use*
  • Cardiovascular Diseases / prevention & control
  • Cardiovascular Diseases / psychology*
  • Combined Modality Therapy
  • Depression / diet therapy*
  • Depression / drug therapy
  • Dietary Supplements* / adverse effects
  • Double-Blind Method
  • Fatty Acids, Omega-3 / adverse effects
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Humans
  • Intention to Treat Analysis
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Secondary Prevention
  • Sex Characteristics
  • Tetrahydrofolates / adverse effects
  • Tetrahydrofolates / therapeutic use
  • Vitamin B 12 / adverse effects
  • Vitamin B 12 / therapeutic use
  • Vitamin B 6 / adverse effects
  • Vitamin B 6 / therapeutic use
  • Vitamin B Complex / adverse effects
  • Vitamin B Complex / therapeutic use*

Substances

  • Antidepressive Agents
  • Fatty Acids, Omega-3
  • Tetrahydrofolates
  • Vitamin B Complex
  • Vitamin B 6
  • Vitamin B 12
  • 5-methyltetrahydrofolate

Associated data

  • ISRCTN/ISRCTN41926726